Filing Flows › Immunome (IMNM) › Q2 2025 › vs Q1 2025
Immunome (IMNM) Q2 2025 vs Q1 2025 (quarter over quarter)
Immunome's revenue rose $1.1M (+37%) from $2.9M in Q1 2025 to $4.0M in Q2 2025.
Immunome, Q2 2025: revenue $4.0M (+70% year over year), net loss $43.4M, operating cash flow −$49.4M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q2 2025 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $4.0M | $2.9M | $1.1M | +37% |
| Other income, net | $3.1M | $3.0M | $85K | +3% |
| Net loss | $43.4M | $41.6M | $1.8M | +4% |
| Costs & expenses | $50.5M | $47.6M | $2.9M | +6% |
| Operating costs | $50.5M | $47.6M | $2.9M | +6% |
| Research & development | $40.5M | $36.9M | $3.6M | +10% |
| General & admin | $10.0M | $10.7M | −$648K | -6% |
| Operating cash sources | $55.4M | $59.4M | −$4.0M | -7% |
| Depreciation & amortization | $637K | $611K | $26K | +4% |
| Share-based compensation | $5.3M | $5.7M | −$356K | -6% |
| Cash used in operations | $49.4M | $53.1M | −$3.7M | -7% |
| Net loss absorbed | $43.4M | $41.6M | $1.8M | +4% |
| Working capital & other | $12.0M | $17.7M | −$5.7M | -32% |
Questions
How much did Immunome's revenue grow quarter over quarter in Q2 2025?
Immunome's revenue rose $1.1M (+37%) from $2.9M in Q1 2025 to $4.0M in Q2 2025.